Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)

M.D. Anderson Cancer Center13 enrolled

Overview

The goal of this research is to see if giving the drug SCH66336 by mouth can improve the disease in patients with chronic or accelerated phase CML. The safety of this treatment will also be studied.

Objectives for this study are two-fold: 1. To determine the efficacy of SCH66336 in patients with chronic phase and accelerated phase CML in relation to response rate, duration of response, and survival. 2. To assess the toxicity of SCH66366 in these patients.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Myelogenous Leukemia, Chronic

Interventions

SCH66336DRUG

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

* Diagnosis of Philadelphia chromosome (Ph) -positive CML in chronic or accelerated phase; * Failure to respond to or intolerance to imatinib mesylate (Gleevec); * Age \>/= 16 years; * Life expectancy of \>/= 2 months; * Performance status 2 or better (Zubrod); * Adequate renal and hepatic functions (creatinine and bilirubin \</= 2 mg/dl); * Adequate cardiac function; * Not candidates for or have refused allogeneic transplantation; * Patients should not be receiving azoles (ketoconazole, itraconazole, fluconazole), macrolides, HIV protease inhibitors, cyclosporin or anti-seizure drugs (phenobarbital, phenytoin, carbamazepine), rifampin or isoniazid.

Locations (1)

MDAnderson Cancer Center

Houston, Texas, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.